ArticleBMJ open2022

Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial.

Simeon Schietzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.